Skip to main content

Table 3 Results of gait testing

From: Investigating the role of neuropathic pain relief in decreasing gait variability in diabetes mellitus patients with neuropathic pain: a randomized, double-blind crossover trial

Characteristic

Pregabalin intervention - baseline (n = 19)

Pregabalin intervention - final (n = 19)

Placebo intervention - baseline (n = 19)

Placebo intervention – final (n = 19)

Cadence (Steps/Minute)

137.0 ± 24.9

126.5 ± 24.2

137.4 ± 21.9

140.6 ± 22.9

Duration of Time to Walk 50 Metres (seconds)

39.8 ± 0.8

40.2 ± 1.1

39.7 ± 0.7

39.5 ± 0.9

Average Step Length (metres)

0.55 ± 0.11

0.59 ± 0.13

0.55 ± 0.15

0.54 ± 0.15

Average Step Duration (seconds)

0.44 ± 0.08

0.47 ± 0.09

0.44 ± 0.07

0.43 ± 0.07

Step Length Variance

0.060 ± 0.002

0.087 ± 0.010*

0.098 ± 0.005

0.100 ± 0.003

Step Velocity Variance

0.043 ± 0.001

0.066 ± 0.003*

0.058 ± 0.003Ψ

0.038 ± 0.000κ

  1. Values shown are means ± standard deviations. MANOVA testing was used for step length/velocity variance comparisons. ANOVA testing was used for other measures shown. *p < 0.025 for comparison of baseline and final visit testing in the pregabalin intervention period. Ψp < 0.025 for comparison of baseline visit testing for the pregabalin and placebo intervention periods. κp < 0.025 for comparison of baseline and final visit testing in the placebo intervention period.